Extracorporeal immunoadsorption of circulating specific serum factors in cancer patients. by Langvad, E. et al.
Br. J. Cancer (1975) 32, 680
EXTRACORPOREAL IMMUNOADSORPTION OF CIRCULATING
SPECIFIC SERUM FACTORS IN CANCER PATIENTS
E. LANGVAD,* H. HYDEN, t H. WOLF AND N. KROEIGAARD
From *the Fibiger Laboratory Ndr. Frihavnsgade 70, DK-2100 Copenhagen 0, Denmark, tThe Institute
of Neurobiology, University of Goteborg, Goteborg, Sweden, and the Surgical Departments H andD,
University Hospital Copenhagen, Gentofte, Denmark
Received 27 June 1975 Accepted 26 August 1975
Summary.-Circulating serum factors have been said to abrogate the effects of
immune response in cancer, i.e. "blocking" and "antigenic inhibition". The aim of
this investigation was to isolate such specific factors in a purified and native state.
F(ab')2 fragments isolated from hypernephroma were insolubilized on the surfaces
of an extracorporeal perfusion chamber which was inserted into the circulation by
means of an arterio-venous shunt. As a result, 3 proteins not present in normal
serum were isolated and eluted for further study. In immunoelectrophoresis the
3 proteins were specifically precipitated by heterologous (rabbit) antihypernephroma
serum but not by anti-serum directed against normal serum components. More-
over C 9 components, C 3 activator and C 3 were isolated in the chamber, the
latter complement factor in large concentrations. This further sustained that
specific antigen-antibody reactions had occurred in the chamber. One of the 2
patients studied was perfused for 60 h and 40 min. During this period 450 litres
of blood were brought into intimate contact with the immunoadsorbent. Proteins
in amounts sufficient for immunochemical analysis were isolated within 3 h.
TUMOUR associated antigens (TAA)
on tumour cell membranes provoke the
host immune system to react. In a large
variety of human tumours, cytotoxic
lymphocytes and humoral antibodies
appear to cross-react specifically with
allogeneic tumour cells of the same type.
The presence on the tumour cell
membranes of common TAA readily
recognizable by the host immune system
might be viewed with approbation had
they remained in their original location.
However, far from being a static structure,
the cell membrane may exfoliate TAA
into the circulation and this may be
viewed with equal dismay. Free antigen
or antigen-antibody complexes may
occupy the specific receptors of activated
lymphocytes or mask the specific anti-
genic sites at the the tumour cell level
(Currie and Basham, 1972; Hellstrom
et al., 1973; Baldwin, Embelton and
Price, 1973; Currie 1973 a, b; Jose and
Seshadri, 1974). In both events "anti-
genic inhibition" or "blocking" may
protect the tumour cells from immune
mediated destruction.
Thus, according to present concepts,
circulating serum factors may be attrib-
uted a "smoke screen" effect, facilitating
the escape of tumour cells from the cyto-
cidal effect of the immune response.
Future immune therapy in cancer
involves the control of "antigenic inhib-
ition" and "blocking". This might be
achieved if the circulating serum factors
could selectively be removed from the
bloodstream. The present study was
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undertaken toward this end and with the
aim of isolating specific serum factors in
a native purified state.
The main difficulty was the production
of heterologous antibodies specific for
TAA and non-reactive with normal serum
components. TAA reveal their presence
only in biological test systems. Tumour
extracts containing TAA are dominated
by a large variety of normal proteins.
Various fractionation procedures may
somewhat reduce the amount and number
of irrelevant proteins. However, the
chances of selecting and purifying the
relevant but unknown proteins by con-
ventional means are slim. Extensive
purification procedures also may result in
conformational and antigenic alterations
of the native TAA.
Theoretically, antibodies raised against
unfractionated tumour extracts might
be rendered oligo- or monospecific through
extensive absorption. However, com-
plete absorption ofanti-normal specificities
is difficult to achieve and partial identities
with normal antigens might also result
in absorption of the desired antibody
specificities.
Most tumour extracts contain con-
siderable amounts of immunoglobulins
(Thunold, Tonder and Larsen, 1973).
The assumption that these immunoglobu-
lins might be autologous tumour specific
antibodies has gained support through
recent observations (Philips and Lewis,
1971; Irie, Irie and Morton, 1974; Gupta
and Morton, 1975).
In the present study, heterologous as
well as homologous immunoglobulins
eluted from tumours have been used as
immunoadsorbents for circulating serum
factors.
MATERIALS AND METHODS
Specimens. A pool of liver metastases
from colonic carcinomata (cc) were obtained
10 h post mortem. Two hypernephromata
(hyp.a and hyp.b) were obtained surgically.
Extraction of antigens. All procedures
were carried out in the cold. Tumours (cc
and hyp.a) were cut in small pieces, rinsed
briefly in water, minced and homogenized for
5 s in equal volumes of 0.14 mol/l NaCl using
an Ultra Turrax (Janke and Kunkel KG,
Staufen/Br., Germany). Homogenates were
eluted repeatedly in decreasing (0-14-0-01
mol/l) concentrations of NaCl. Washing was
stopped when the supernatants showed only
minimal turpidity after centrifugation (800
g for 10 min). The pooled supernatants were
centrifuged at 80,000 g for 30 min. The
pellet was suspended in 3 vol of 3 mol/l KCI
in phosphate buffered saline (pH 6.9) and
extracted for 16 h on a rotatory shaker in
the cold room. The extracts were centrifuged
(80,000 g for 30 min) and dialysed against
physiological saline for 16 h. The extracts
were concentrated by placing the dialysis bags
in dry Aquacide 2 (Calbiochem). After a
final centrifugation (80,000 g for 30 min)
protein determinations were carried out
according to Lowry et al. (1951). The anti-
gen preparations were stored at -80°C.
Elution of immunnoglobulins.-Hyperne-
phroma (hyp.b) was cut and rinsed as above.
The tissue was homogenized in 4 vol of phos-
phate buffered 15% NaCl (pH 7.4) and incu-
bated for 2 h at 37°C on a magnetic stirrer.
After centrifugation at 1000 g for 10 min the
supernatant was saved and the procedure was
repeated. Immunoglobulins were precipi-
tated from the combined supernatants by the
addition of 0 25 g ammonium sulphate/ml.
Subsequent purification of IgG and IgA was
carrried out as described byIngild and Harboe
(1973). The method implies that IgM is lost.
The immunoglobulins for use in the perfusion
chamber were sterilized by Millipore (Millex)
filtration and the protein content determined
as above.
Antisera.-Antibodies against tumour
extracts were raised in rabbits. Fifty ul
doses of antigen extracts containing 2 mg of
protein were emulsified in equal volumes of
Freund's incomplete adjuvant and adminis-
tered at multiple intradermal sites. The dose
was repeated every other week for 3 months
when bleeding was commenced.
The anti-cc antiserum for use in the extra-
corporeal perfusion chamber was absorbed
with washed AB Rh positive cells and spleen
cells (autopsy material) whichhadbeenpassed
through a fine meshed steel screen and washed
in saline. Further absorption was carried
out with glutaraldehyde insolubilized human
plasma (Avrameas and Ternynck, 1969).
All absorption procedures were repeated
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twice. Antisera for use in immunoelectro-
phoresis were not absorbed.
The immunoglobulins were isolated from
the antisera and purified according to Ingild
and Harboe (1973). Monospecific anti-
bodies against complement factors were made
available by Hoechst, Copenhagen. Mono-
specific antibodies were otherwise purchased
from Dakopatts, Copenhagen.
Immunoelectrophoresis.-The crossed im-
munoelectrophoresis and its variants were as
describedbyAxelsen, KroellandWeeke(1973).
Autoradiography.-For use in autoradio-
graphy, purified immunoglobulins eluted
from hypernephroma (hyp.b) were labelled
with 125J, either by the chloramine-T method
(Hunter, 1971) or by the lactoperoxidase
method (Marchalonis, Cone and Santer, 1971).
The electrophoresis gels were washed and
incubated directly with labelled immuno-
globulins in incubation buffer. The proced-
ures were otherwise as described by Weeke
and Loewenstein (1973). Autoradiography
was performed on Kodak medical x-ray film
(Blue brand BB 54) with an exposure time of
20-40 h.
Perfusion chambers.-A newly constructed
extracorporeal perfusion chamber was em-
ployed to catch selectively circulating serum
factors (Hyden et al., 1974). Once immo-
bilized on the surfaces of the chamber by an
antibody-antigenreaction,thefactorstrapped
were eluted in order to be characterized in a
native and purified state.
The extracorporeal chamber is made from
optical quality polymethyl methacrylate
and contains 23 0 9 mm thick 150x 100 mm
plates of the same material (Fig. 1) spaced
0 7 mm from each other. The total surface
is 0-5 M2. The inlet (a) is equipped with a
spreading device for the blood. The con-
struction gives a laminar flow necessary for
the passage of a non-Newtonian fluid. The
narrow spacings between the plates ensures
a good plate surface-blood contact. A fluid
collecting device forms the outlet. The
chamber houses 150 ml of blood. It is
usuallv inserted in a Scribner shunt between
FIG. 1.-Expanded view of extracorporeal perfusion chamber.
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the radial artery and a vein; no pump is
usually required at its operation. At a
systolic blood pressure within 130-170 mm
Hg, the blood flow through the chamber is
120-150 ml/min. For polyclinical use, the
chamber is equipped with a control box
containing measuring devices for blood pres-
sure and flow and a signalling buzzer. The
measuring devices operate via the elastic wall
of the tubing and are not in contact with
the blood. The chamber is checked by a
pressure test before use.
The technique for antisera immobilization
covalently attaches the antibodies to the
polymer carrier via a silane derivative accord-
ing to a technique modified after Weetall
(1970). The reagent solutions are pumped
in and through the assembled chamber.
The chamber is sterilized by 5% °glutaral-
dehyde solution for 1 h. This treatment also
constitutesthethirdstepintheimmobilization
procedure to activate the silane derivative.
The solutions are made up from autoclaved
glass, distilled water. After covalently
attaching the antisera, the chamber is filled
with sterile physiological saline containing
streptomycin and placed at 40C. Before
use, usually within 1-5 days, this saline sol-
ution is replaced by rinsing with 21 of sterile
saline. The last filling is replaced by blood
at the insertion ofthe chamberinto the shunt.
The effectivity of sterilization was monitored
continuously by bacteriological tests and
found satisfactory.
Another important factor is the validity
of the covalent bonding of the protein to the
carrier surface. In patients treated by
L-asparaginase chambers, no allergic sym-
toms have been observed during or after
treatment for 30 to > 400 h up to a period
of 2 years, nor was any antibody against
asparaginase detected in the blood of these
patients.
The chamber is inserted into the blood
circulation for 3-6 h at a time. The patients
have received a total of 5000-10000 i.u. of
heparin during the course of each treatment.
The patients reported here also have received
Marevan (warfarin sodium) yielding a pp
level of 8-12. The most important factors
to be considered in chamber construction to
avoid coagulation are: (1) blood compatibility
ofthe material andsuitabilityfortheimmobil-
ization reactions; (2) smoothness of the
surfaces, checked by scanning electon micro-
scopy. The plates are moulded and the sur-
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face is remarkably smooth at the 2-5 nm
level. Few white cells or thrombocytes are
observed adhering to the surfaces after per-
fusion for 4 h; (3) Correct laminar flow with
a velocity of at least 5 cm/s; (4) a chamber
temperature of 32-37°C at perfusion main-
tained by an electrically heated cloth or by
immersion of the chamber in 37°C water.
At the end ofeach perfusion period (3-5 h)
the arterial shunt was clamped while physio-
logical salinewasinfusedthroughthechamber
until the 150 ml volume of blood remaining
in the chamber was pressed back into the
circulation. The arterial and venous parts
of the shunt were coupled and the chamber
was perfused with enough saline to remove
visible traces of blood.
In order to elute proteins caught on the
chamber surface, the following steps were
taken under sterile conditions:
A 1000 ml volume of physiological saline
was rapidly perfused through the chamber
and collected. This was followed by incu-
bation at pH 2-8 (Tris-glycine) for 30 min
at 18°C. 600 ml of Tris glycine were then
perfused and the pH of this perfusate was
adjusted immediately to 7-0. As an alter-
native incubation procedure, the chamber
was incubated with PBS, pH 7 4 containing
0-25% trypsin (Difco) for 20 min at 180C.
Then 600 ml of physiological saline were
perfused and collected.
Trasylol (Bayer) was immediately added
to all eluates to give a final concentration of
12,500 u/1000 ml. Saturated ammonium
sulphate was added to a final 2/3 saturation.
After 16 h at 4°c, the precipitates were sedi-
mented by centrifugation at 25,000 g, redis-
solved and dialysed for 20 h against 0.9%
NaCl and finally concentrated by placing the
dialysis bags in dry Aquacide II. The con-
centrated eluates were stored at -80°C.
After washing with a further 2000 ml of
saline, the eluted chambers were again ready
for use and could be stored at 4°C.
Patient8.-Case I. 21.04.28 K.K.L.,female.
Carcinoma of the colon with metastases to
liver and lungs. Terminal stage after pal-
liative hemicolectomy 9 months earlier.
The patient had received chemotherapy as
well as steroids (prednisone). Total per-
perfusion time was 7 h. Three chambers
were activated with native heterologous
anti-cc antibodies.
Case IL.04.04.20, P.B.A.S., male. Hyper-
nephroma with metastases to the left lung.
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Two solitary metastases in the basal and
perihilar regions of the left lung. X-ray
examination, scintigraphy and ultrasonic
scanning revealed no further metastases.
Perfusion was started 14 days after nephrec-
tomy. The patient received no other treat-
ment. Eight chambers were activated with
homologous immunoglobulins eluted from
hypernephroma (hyp.b).
To remove Fe terminals the activated
chambers were incubated with 0I1%, 2 x
crystallized pepsin (Sigma) (in 0-07 mol/l
acetate buffer (pH 4.5) containing 0 05 mol/l
NaCl) for 18 h at 370C and subsequently
washed with 2000 ml of physiological saline.
Eighteen perfusions totalling 60 h and 40 m
were carried out.
RESULTS
Perfusion of Patient I resulted in the
withdrawal of large quantities of cells
from the circulation. After the chambers
were rinsed with saline to remove blood, it
wasevident thatlarge, macroscopic aggre-
gates of white cells had built up on the
chamber surfaces. The chambers, nor-
mally clear and transparent, appeared
completely opaque. Large clumps of
cells were seen breaking loose and falling
into the chamber fluid. On microscopy,
the cells proved to be lymphocytes, mono-
cytes and neutrophils. The chambers
were disassembled and the cell scraped
off, resuspendedandcounted. Itappeared
that cells on the order 109 had been
retained in the 3 chambers.
Since any TAAretained in the chamber
would be heavily contaminated with
proteins derived from white cells, no
serious attempt to isolate specific serum
factors from the chambers could be made.
Crossed electrophoresis of proteins eluted
from the chambers against rabbit anti-
whole human serum proteins revealed 4
serum proteins, among these IgG.
Perfusion was carried out on Days 1
and 2. On Day 3 peripheral blood smears
showed 6% staff forms, 1% metamye-
locytes and 1% myelocytes. On Day 5
lymphocyteshaddroppedfrom 12% to2%.
Lymphocytes had risen to 10% on Day 9
when the third perfusion was carried out.
On Day 15 lymphocytes hadagaindropped
to 3%. On Day 18 the lymphocyte
count had returned to the pre-perfusion
level (10-17%). The monocyte and
eosinophil counts were not affected by
the perfusions. Throughout the obser-
vation period the total white cell count
remained between 10,000 and 15,000.
TABLE.-Proteins Isolated from Hypernephroma Patient Analysed by Crossed
Immunoelectrophoresis
Antibodies
Monospecific
x- 1-lipoprotein
fl-lipoprotein
Albumin
Transferrin
ax-2-macroglobulin
a-1-antitrypsin
fl-2-microglobulin
IgA
IgG
IgM
Clq-component
Cls-inactivator
C4 (fl-1-E-globulin)
C3 (fl-il-A. fl-I-C-globulin)
C3-activator
C9-components
Unidentified serum protein
Protein precipitate A
Protein precipitate B
Protein precipitate C
Trypsin
trace
trace
trace
+
+
trace
+
Anti-whole serum
trace
+
+
trace
Anti-hypernephroma
+
+
trace
5~~~~~
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FIG. 2. Crossed immunoelectrophoresis with intermediate gel. Antigen: proteins eluted from per-
fusion chamber at pH 2-8. First dimension: 30 min, 8V/cm. Anode to the left. Antibodies: I-
rabbit anti-human whole serum protein. II- rabbit anti-hypernephroma (hyp.a). Second dimen-
sion: 18 h, 1V/cm. Anode at the top. Staining: Coomassie brilliant blue R. Arrows on: (1) albumin,
(2) a-l-antitrypsin, (3) a-2-macroglobulin, (4) complement C3, (5) IgG, (6) C3-activator, 7) protein
A, (8) protein B, (9) protein C.
Perfusion of Patient II resulted in
hardly any cells adhering to the surface of
these pepsin treated chambers. After
rinsing with saline, a fine greyish layer
of protein was seen covering the surfaces.
After elution as described, the chambers
had regained their original clearness and
transparency.
During the second perfusion, the
patient experienced shivering andasudden
rise of temperature but apart from this
episode the perfusion treatment was
tolerated without side-effects. No
changes of the peripheral blood attribut-
able to the perfusion were noted and no
signs of haemolysis were detected. The
lowhaemoglobin level persisting in spiteof
blood transfusions should be viewed as
secondary to the presence of metastases
as well as to impaired kidney function
(serum creatinine 2.6).
Thirteen different proteins were eluted
from the chambers, some intrace amounts.
Nine proteins have been identified by
crossed immunoelectrophoresis (Table,
Fig. 2). Among these were albumin,
ac-2-macroglobulin and oc-l-antitrypsin
(proteins knowntoassociatenonspecifically
with IgA or immune complexes) and
transferrin. Furthermore IgG, IgA,
complement C3 (Fig. 3), C3 activator and
C9 were identified. One serum protein
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FIG. 3.-Crossed immunoelectrophoresis with intermediate gel. Antigen: proteins eluted from per-
fusion chamber with saline. First dimension: 30 min, 8V/cm. Anode to the left. Antibodies:
I - rabbit anti-human whole serum protein: II - rabbit anti-hypernephroma (hyp.a). Second
dimension: 17 h, 1 V/cm. Anode at the top. Staining: Coomassie brilliant blue R. Arrows on:
(1) albumin, (2) n-1-antitrypsin, (3) a-2-macroglobulin, (4) protein C, (5) complement C3.
precipitated by anti-whole serum as well
as by anti-hypernephroma remains un-
identified. Three proteins (Fig. 4) were
precipitated only by anti-hypernephroma
antibody (precipitate A, B and C).
To determine which of the proteins
had been caught in the perfusion chamber
through specific immunochemical binding,
the electrophoresed gels were incubated
with 1251 labelled immunoglobulin eluted
from hypernephroma (hyp.b), i.e. the
immunoglobulin identical to that insolu-
bilized in the chambers.
Subsequent autoradiography revealed
that precipitates A, B, and C (Fig. 5) as
well as complement C3 (Fig. 6) had been
labelled (for comparison see Fig. 3, 4). In
a control plate with normal serum proteins
the precipitates ofIgG and IgA alone were
labelled.
Perfusions were carried out over 3
periods. There were 14-day intervals
between these periods. The amount of
proteins A, B and C isolated within each
perfusion period decreased progressively
and the proteins were hardly demonstable
at the termination of each period. When
perfusions were resumed after the recrea-
tive intervals the 3 proteins were again
isolated in amounts as originally.
DISCUSSION
A large number of white cells were
retained in the chambers during perfusion
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FIG. 4. Crossed immunoelectrophoresis with intermediate gel. Antigen: proteins eluted from per-
fusion chamber after trypsinization. First dimension: 30 min, 8V/cm. Anode to the left. Anti-
bodies: I - rabbit anti-human whole serum protein. II - rabbit anti-hypernephroma (hyp.a).
Second dimension: 21 h, IV/cm. Anode at the top. Staining: Coomassie brilliant blue R. Arrows
on: (1) protein A, (2) protein B, (3) protein C, (4) unidentified serum protein, (5) complement C3.
of Patient I. The heterologous anti-
colonic carcinoma (cc) antibodies insolubil-
ized in the perfuson chambers had been
adsorbed as described. In spite of this, a
certain reactivity against human immuno-
globulins persisted. This fact may be
considered the major reason why lympho-
cytes, monocytes and neutrophils were
retained in large amounts. Circulating
TAA, antigen-antibody complexes and
cells carrying TAA on their surface, i.e.
"inhibited" T lymphocytes, might be
expected to be retained specifically.
Furthermore, cells with surface immuno-
globulin would be recognized and retained
and so would serum immunoglobulins.
As a consequence of the reaction with
heterologous anti-human immunoglobulin,
the Fe portion of the complexed serum
immunoglobulin is exposed effectively.
Thus, all cells with Fc receptors may now
attach to the chamber surface. Itappears
from this unexpected and certainly un-
wanted experience, that heterologous anti-
body for use in the perfusion chamber
must be highly specific and furthermore
that the use of F(ab')2 rather than native
immunoglobulin is essential.
Antigen preparations derived from
tumour cell membranes are composed of
a large number ofproteins. Among these
IgG, IgA and complement C3 are espec-
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FIG. 5.-Autoradiograph ofcrossed immunoelectrophoresis with antigen and antibodies corresponding
to Fig. 4. Precipitates A, B and C have been labelled.
ially conspicuous. Circulating specific
humoral antibodies have been demon-
strated in a variety ofhuman malignancies
(Hellstr6m et al., 1968; Lewis et al., 1969;
Eilber and Morton, 1970; O'Neill and
Romsdahl, 1974), and it has therefore been
reasonableto assumethatimmunoglobulins
eluted from solid tumours might contain
specific anti-tumour antibodies. Indeed,
evidence has been presented that immuno-
globulins eluted from human melanomata
are specific, cross-reactive (Gupta and
Morton, 1975) and complement dependent
(Irie et al., 1974).
Perfusion of Patient II using homo-
logous immunoglobulins resulted in a
minimal catch of cells. This may be
attributed to the fact that no anti-human
immunoglobulin was present as well as to
the lack of Fc portions. Ten different
serum proteins as well as 3 proteins not
present in normal serum could be isolated
from the chambers. Albumin, o-l-anti-
trypsin (Laurell and Thulin, 1975) and
a-2-macroglobulin are known to form
complexes with immunoglobulins. The
latterprotein was presentin trace amounts
and so was transferrin and IgA. Ofthe 3
non-serum proteins (precipitate A, B, and
C) 2 were isolated in considerable amounts.
Asevaluated bypeak height, IgGwaspres-
ent in fair amounts, complement C3 in
large amounts, while C3 activator and C9
components were found in trace and small
amounts respectively. Complement
factors preceding C3 in the complement
cascade were not found.
The fact that only 10 serum proteins
out of the 42 proteins recognizable in
normal serum were isolated, and also the
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FiG. 6.-Autoradiograph of crossed immunoelectrophoresis identical to the one shown in Fig. 3.
Complement C3 has been labelled.
finding that the proteins were isolated in
relative quantities disproportionate to the
amounts in serum, strongly indicate that
specific immunochemical reactions have
occurred. Comparedwiththenumberand
relative amounts of proteins present in
hypernephroma antigen preparations
(Fig. 7) it appears that a selective binding
in the chamber has resulted in the con-
centration of circulating proteins present
in low amounts.
Since the chambers had been treated
with pepsin, the insolubilized IgG lacking
Fc portions was unable to fix complement
Cl after reaction with antigen. On the
other hand, the C3 component may be
activated without the co-operation of
Cl, C4 and C2. This alternative pathwav
is activated by a serum enzyme system
and the finding of C3 activator may indi-
cate that this mechanism may have been
operative in the chambers. Thus, while
some of the proteins eluted from the
chambers have been fixed through non-
specific complex formation, the finding of
proteins A, B and C along with IgG, C3,
C3 activator and C9 components indicates
that specific antigen-antibody reactions
have taken place. The autoradiographic
evideAice further supports the assumption
that the 3 proteins precipitated by anti-
hypernephroma antibody are proteins
shared by hypernephroma patients and
recognized as "non-self" by the immune
system of these patients.
In the control autoradiographs with
normal serum proteins, only precipitates
IgA and IgG were labelled. This might
be expected since these precipitates con-
tain a surplus of heterologous antibody
against human IgG and IgA.
For controlpurposestheelutedproteins
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FIG. 7.-Crossed immunoelectrophoresis. Antigen: 3 mol/l KCl extract of cell membranes derived
from hypernephroma (hyp.a). First dimension: 30 min 8V/cm. Anode to the left. Antibody:
rabbit anti-hypernephroma (hyp.a). Second dimension: 17 h, 1 V/cm. Anode at the top. Staining:
Coomassie brilliant blue R.
were electrophoresed against antisera
raised against other tumour types i.e.
anti-prostatic carcinoma (pooledmaterial),
anti-colonic carcinoma, anti-oral carcin-
oma (pooled material) and 4 different
anti-melanoma sera. In these combin-
ations and with anti-human whole serum
in the intermediate gel, no precipitates
were formed in the zones containing the
various anti-tumour antisera. It may be
concluded therefore that antigens A, B and
C are proteins present in hypernephroma
a, hypernephroma b as well as in the
cirulation of Patient II, whereas they are
not present in prostatic, colonic or oral
carcinoma andneither in malignantmelan-
omata. The possibility that proteins A,
B and C might be bacterial antigens
appears unlikely since in this case the
same bacterial antigens should have been
present in all 3 hypernephroma cases but
absent in the remaining tumours and
tumour pools used in the production of
the anti-tumour antisera applied in the
control electrophoreses.
As to the nature of proteins A, B and
C, it may be stated thatthey are not HL-A
antigens nor modifications of these.,8-2-
microglobulin is physically linked to the
HL-A polypeptide (Rask et al., 1974) and
this protein could not be demonstrated
in immunoelectrophoresis against mono-
specific anti ,-2-microglobulin.
Autoantibodies with anti-lipoprotein
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specificity in patients with cancer have
been reported (Riesen etal., 1975). Appa-
rently no such specificities were present in
the immunoglobulins insolubilized in the
chambers since lipoproteins could not be
detected among the proteins isolated.
The antibodies raised against tumour
extracts for use in immunoelectrophoretic
analysis contain specificities directed
againstanumberofserumproteins. How-
ever, the use of intermediate gels con-
taining anti-whole serum protein permits
the resolution of serum and non-serum
proteins.
Patient I died 29daysaftertermination
ofthe perfusion. Autopsyrevealedexten-
sive necrotic metastases to lungs, liver
adrenals and paraaortic lymph nodes.
The clinical condition of Patient II is
good. As evaluated by repeated tomo-
graphies, the 2 metastases in the left lung
remain unchanged 4 months postopera-
tively with diameters of 2'0 and 2-3 cm
respectively.
It is debatable whether such attempts
as these to "unblock" the immune system
may be successful in the presence of
metastases of this magnitude, probably
exceedingthecapacityofanintact immune
system.
The use of extracorporeal, specific
immunoadsorption, however, may greatly
increase the current scanty knowledge
of just what tumour associated antigens
are, not to mention the possibilities of
future specific immune therapy in cancer.
We would like to express our gratitude
for the expert technical assistance of Mrs
Lene Kureer, Mrs Inger Heiberg, and Miss
Birgitte Christiansen.
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